On the stock market since 2020, it operates in the world of health and science. It has 77,000 employees. Now — the numbers.
This is an established company with proven profits.
The biggest line carries real weight, but it doesn’t decide everything on its own.
The gap is $18.3B. In times of high interest rates, a gap like that can squeeze a company.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 20% below its peak. The market has trimmed its expectations for the company.
It pays out $3.00 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
No clear buy-side message is coming from the executive floor. Council score: 3/10.
On our five-subject report card, BDXB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BDXB is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.